Freenome
Freenome is an AI-enabled diagnostics company focused on early cancer detection through blood-based multiomics. Its platform uses machine learning to analyze biological signals across molecular data types, aiming to detect cancer earlier and support screening pathways.
- Highest 2026 tier: Tier II
- AI-Enabled Diagnostics Providers
- 3 ranking categories
Overview
Freenome is an AI-enabled diagnostics company focused on early cancer detection through blood-based multiomics. Its platform uses machine learning to analyze biological signals across molecular data types, aiming to detect cancer earlier and support screening pathways.
Freenome’s relevance lies in the convergence of AI, molecular diagnostics, and preventive oncology. Early cancer detection is one of the most clinically and commercially important applications of AI-enabled diagnostics because it requires identifying weak biological signals from complex datasets.
Freenome is included in 3 2026 ranking categories. Its highest classification is Tier II. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | Freenome |
| Founded | 2014 |
| Institution type | AI-Enabled Diagnostics Providers institution |
| Headquarters | South San Francisco, United States |
| Primary focus | AI-Enabled Diagnostics Providers |
| Highest 2026 ranking tier | Tier II |
Principal activities
Freenome’s relevance lies in the convergence of AI, molecular diagnostics, and preventive oncology. Early cancer detection is one of the most clinically and commercially important applications of AI-enabled diagnostics because it requires identifying weak biological signals from complex datasets.
Core capability
AI-Enabled Diagnostics Providers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
AI-Enabled Diagnostics Providers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
The company’s platform is still more specialized and development-stage than mature imaging AI providers, but its AI-enabled multiomics approach makes it strategically important in the future direction of diagnostics.
Freenome is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier II.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Freenome should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Freenome. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Freenome |
| Headquarters | South San Francisco, United States |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 AI-Enabled Diagnostics Providers 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Genetic Testing & Genomics Providers 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Precision Medicine Diagnostics Providers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
